Seelos Therapeutics Announces Year End 2020 Business Update
-Highlights of Continued Execution of Plans for Multiple Clinical Programs and Upcoming Catalysts
-Additions to the Clinical, Operational and Regulatory Teams
News provided by
Share this article
Share this article
NEW YORK, Jan. 6, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year end 2020 business update. This past year marked the most significant 12 months in Seelos Therapeutics history despite being an otherwise challenging year due to the COVID-19 pandemic. We completed our safety trial for the intranasal ketamine program and began opening centers for our pivotal trial for Acute Suicidal Ideation and Behavior in patients with major depressive disorder. The trehalose program s pivotal study in ALS was accepted into the HEALEY ALS Platform
Cornell Adjusts Testing Procedures Jan. 28, 6:15 a.m. Cornell University on Wednesday announced changes in its COVID-19 testing procedures. University officials said they were pleased with the low rates of infection in the fall semester, but wanted to learn from them. During the fall, most test results were available within 24 hours. In the spring, 80 percent of test results
HealthCare Royalty Management: HCR Expands Team and Announces Promotions
Expansion of West Coast Presence:
HCR has appointed Matthew H. Bullard as a Managing Director based in San Francisco, CA. We are very pleased to welcome Matt to the HCR team, said Clarke B. Futch, Chief Executive Officer and Chairman at HCR. With over two decades of healthcare experience, Matt brings a wealth of knowledge and relationships to HCR. Matt will round out HCR s team on the West Coast, which has been one of our most important markets. Matt s addition along with HCR s existing professionals on the West Coast, Sean Mansoory, Mardi Dier (Senior Advisor) and Gary Lyons (Senior Advisor), demonstrates HCR s commitment to its regional model and provides the firm with more scale and depth to better serve the needs of biopharmaceutical companies in that region.
Bible site where John The Baptist sentenced to death is found by archaeologists
John The Baptist was supposedly executed at the Fortress of Machaerus, near the Dead Sea in Jordan. A historian believes he has discovered a courtyard where his fate was sealed
13:43, 6 JAN 2021
John The Baptist s execution was ordered around AD 29 by King Herod Antipas, according to The Bible (Image: Getty Images/iStockphoto)
The Daily Star s FREE newsletter is spectacular! Sign up today for the best stories straight to your inboxInvalid EmailSomething went wrong, please try again later.
Sign up today!
When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.
Triangle Insights Group Announces Key Leadership Promotions
Share Article
Premier life sciences consulting firm announces promotions within leadership team
Megan and Ryan have demonstrated consistent excellence in client delivery across a breadth of consulting engagements. They have become not only internal leaders among their peers here at Triangle, but also key thought leaders for clients. DURHAM, N.C. (PRWEB) January 06, 2021 Triangle Insights Group has announced that both Ryan Coe and Megan Thomas have been named as Principals and now join the senior leadership team at the firm.
Ryan is a tenured consultant with significant experience in portfolio strategy, advanced data analytics, and commercial forecasting. Ryan completed a fellowship in Bioengineering at the Massachusetts Institute of Technology and received a Ph.D. in Bioengineering from the University of Washington, where he was a National Science Foun